 |
21 Diseases |  |
8 Trials |
|
8 Trials |  |
156 News |  |
| 12» |
- | azeliragon (TTP488) / Cantex Pharma
Journal: RAGE Is Essential for Subretinal Fibrosis in Laser-Induced Choroidal Neovascularization: Therapeutic Implications. (Pubmed Central) - Jun 9, 2025
The role of RAGE in EMT was studied in cells pretreated with RAGE antagonists (FPS-ZM1 or azeliragon), followed by cotreatment with TGF-?2 for 48
- | Trial completion date, Trial primary completion date: RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) - May 23, 2025
P1/2, N=48, Recruiting, Sponsor: Georgetown University
The role of RAGE in EMT was studied in cells pretreated with RAGE antagonists (FPS-ZM1 or azeliragon), followed by cotreatment with TGF-?2 for 48 Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Mar 2025 --> Oct 2025
- azeliragon (TTP488) / Cantex Pharma
A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION). (Hall A - Posters and Exhibits; Poster Bd #: 68) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3508;
P1/2
Azeliragon was safely substituted for corticosteroids in this phase 1 study with no DLTs observed. The early response rate appears encouraging and accrual to the phase II expansion cohort (n = 40) with a primary endpoint of objective response rate is ongoing.
- azeliragon (TTP488) / Cantex Pharma
Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Preliminary results of phase Ib/II CAN-201 NDG trial. (Hall A - Posters and Exhibits; Poster Bd #: 115) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3492;
P1/2
To further explore the safety and efficacy profile of azeliragon, we are now expanding the study to include two additional dose levels of 30 mg/day (L4) and 50 mg/day (L5). Enrollment is currently open for level L4.
- | azeliragon (TTP488) / Cantex Pharma
Enrollment closed: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia (clinicaltrials.gov) - Mar 3, 2025
P2/3, N=144, Active, not recruiting, Sponsor: The University of Texas Medical Branch, Galveston
Enrollment is currently open for level L4. Recruiting --> Active, not recruiting
- azeliragon (TTP488) / Cantex Pharma
The Receptor for Advanced Glycation Endproducts (RAGE) Mediates Bacterial Second Messenger-skewed Allergen and IL-33 Driven Neutrophilic Airway Inflammation in Mice (Room 2006/2008 (West Building, Level 2), Moscone Center; Poster Board # 706) - Feb 24, 2025 - Abstract #ATS2025ATS_5292;
Additional studies were performed using the RAGE-specific small molecule antagonist Azeliragon (AZR)... Overall, these studies demonstrate that RAGE is a critical mediator of the innate immune response to allergen or IL-33 driven neutrophilic airway inflammation associated with the presence of bacterial components, making RAGE an intriguing therapeutic target to reduce aberrant neutrophilia in airway diseases such as severe asthma.
- | azeliragon (TTP488) / Cantex Pharma
Journal, PD(L)-1 Biomarker, IO biomarker: Microbiota-induced S100A11-RAGE axis underlies immune evasion in right-sided colon adenomas and is a therapeutic target to boost anti-PD1 efficacy. (Pubmed Central) - Jan 18, 2025
Our findings unravelled that dysfunctional goblet cells and consequential bacterial translocation activated the S100A11-RAGE axis in right-sided colon ADs, which recruits MDSCs to promote immune evasion. Targeting this axis by Azeliragon improves the efficacy of immunotherapy in colon cancer.
- | azeliragon (TTP488) / Cantex Pharma
Preclinical, Journal: The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer Cell Lines. (Pubmed Central) - Jan 12, 2025
Additionally, Azeliragon modulated the immune suppressive tumor microenvironment in pancreatic cancer by reducing immunosuppressive cells, including M2 macrophages, regulatory T cells, and myeloid-derived suppressor cells, while enhancing CD8+ T cell infiltration. These findings suggest that Azeliragon, by inhibiting RAGE-mediated signaling and modulating immune response, may serve as an effective anti-cancer agent in pancreatic cancer.
- | azeliragon (TTP488) / Cantex Pharma
Journal: Ultrasound-Assisted Synthesis of Pyrazoline Derivatives as Potential Antagonists of RAGE-Mediated Pathologies: Insights from SAR Studies and Biological Evaluations. (Pubmed Central) - Jan 3, 2025
Our investigation identifies phenylurenyl-pyrazoline 2?g as a promising candidate, demonstrating superior efficiency compared to the reference antagonist Azeliragon (IC50=13??M). Compound 2g exhibits potent inhibition of the AGE2-BSA/sRAGE interaction (IC50 = 22
- | Trial completion date, Trial primary completion date: RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) - Dec 26, 2024
P1/2, N=48, Recruiting, Sponsor: Georgetown University
Compound 2g exhibits potent inhibition of the AGE2-BSA/sRAGE interaction (IC50 = 22 Trial completion date: Nov 2024 --> Apr 2025 | Trial primary completion date: Nov 2024 --> Mar 2025
- | azeliragon (TTP488) / Cantex Pharma
Enrollment closed: CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Nov 12, 2024
P1/2, N=18, Active, not recruiting, Sponsor: Cantex Pharmaceuticals
Trial completion date: Nov 2024 --> Apr 2025 | Trial primary completion date: Nov 2024 --> Mar 2025 Recruiting --> Active, not recruiting
- | azeliragon (TTP488) / Cantex Pharma
Enrollment change, Trial withdrawal: Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma (clinicaltrials.gov) - Sep 20, 2024
P1, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting N=21 --> 0 | Not yet recruiting --> Withdrawn
- | azeliragon (TTP488) / Cantex Pharma
Enrollment closed: Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov) - Sep 5, 2024
P2, N=30, Active, not recruiting, Sponsor: Cantex Pharmaceuticals
N=21 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | azeliragon (TTP488) / Cantex Pharma
Journal: Involvement of RAGE in radiation-induced acquisition of malignant phenotypes in human glioblastoma cells. (Pubmed Central) - Jul 28, 2024
Both phenotypes were suppressed by specific inhibitors of RAGE (FPS-ZM1 and TTP488) or by knockdown of RAGE...In addition, ?-irradiation-induced phosphorylation of STAT3 was suppressed by RAGE inhibitors, and a STAT3 inhibitor suppressed ?-irradiation-induced enhancement of cell migration, indicating that STAT3 is involved in the migration enhancement downstream of RAGE. Our results suggest that HMGB1-RAGE-STAT3 signaling is involved in radiation-induced enhancement of GBM cell migration, and may contribute to GBM recurrence by promoting metastasis and invasion.
- ||| azeliragon (TTP488) / Cantex Pharma
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 13, 2024
P1/2, N=30, Recruiting, Sponsor: Cantex Pharmaceuticals
Our results suggest that HMGB1-RAGE-STAT3 signaling is involved in radiation-induced enhancement of GBM cell migration, and may contribute to GBM recurrence by promoting metastasis and invasion. N=18 --> 30 | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
- azeliragon (TTP488) / Cantex Pharma
A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer. (Hall A; Poster Bd #: 176a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3941;
P1/2
RAGE interaction with its ligands, including S100 proteins and HMGB1 released from PDAC cells, promotes PDAC invasion, metastasis, and resistance to 5 FU and Gemcitabine...Secondary endpoints include disease control, overall survival, changes in pain as determined by the Brief Pain Inventory, and changes in ECOG performance status, weight, and serum albumin. The study received regulatory approval and accrual started in June 2023.
- azeliragon (TTP488) / Cantex Pharma
Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial design. (Hall A; Poster Bd #: 391b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3201;
P1/2
The study received regulatory approval and accrual started in September 2023. As of January 2024, recruitment in dose level 1 was completed with 6 patients and 3 patients were already included in dose level 2.
- azeliragon (TTP488) / Cantex Pharma
A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION). (Hall A; Poster Bd #: 390a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3198;
P1/2
Neurocognitive batteries, symptom inventories, and quality-of-life questionnaires will also be administered. Three participants have been enrolled in the starting cohort and are pending DLT assessment.
- Herceptin (trastuzumab) / Roche, azeliragon (TTP488) / Cantex Pharma, Perjeta (pertuzumab) / Roche
RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE). (Hall A; Poster Bd #: 207a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1347;
P1/2
In Cohort 4, 6 patients will receive dose dense doxorubicin and cyclophosphamide (ddAC)...As of 2/1/24, 4 patients have been enrolled, with 4 undergoing screening. At the completion of this trial, we plan a randomized trial to evaluate the role of TTP488 to decrease cardiotoxicity, cancer related cognitive decline and disease recurrence.
- azeliragon (TTP488) / Cantex Pharma
MICROBIOTA-INDUCED S100A11-RAGE AXIS UNDERLIES IMMUNOEVASION IN RIGHT-SIDED COLON ADENOMAS AND IS A THERAPEUTIC TARGET TO BOOST ANTI-PD1 EFFICACY (101 - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4221;
Our findings unraveled that dysfunctional goblet cells and consequential bacterial translocation activated S100A11-RAGE axis in in right-sided colon adenomas, which recruits MDSCs to promote immune evasion. Targeting this axis by Azeliragon improves the efficacy of immunotherapy in colon cancer.
- | azeliragon (TTP488) / Cantex Pharma
Journal, Metastases: S100b Treatment Overcomes RAGE Signaling Deficits in Myoblasts on Advanced Glycation End-product Cross-linked Collagen and Promotes Myogenic Differentiation. (Pubmed Central) - Mar 13, 2024
The addition of S100b (RAGE agonist) recovered the differentiation and fusion of myoblasts, and the addition of RAGE inhibitors (FPS-ZM1 and Azeliragon) inhibited the differentiation and fusion of myoblasts. Our results provide novel insights into the role of the AGE-RAGE axis in skeletal muscle aging, and future work is warranted on the potential application of S100b as a pro-regenerative factor in aged skeletal muscle.
- | azeliragon (TTP488) / Cantex Pharma
Trial primary completion date: CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=18, Recruiting, Sponsor: Cantex Pharmaceuticals
Our results provide novel insights into the role of the AGE-RAGE axis in skeletal muscle aging, and future work is warranted on the potential application of S100b as a pro-regenerative factor in aged skeletal muscle. Trial primary completion date: Dec 2023 --> Dec 2024
- | azeliragon (TTP488) / Cantex Pharma
Trial suspension: Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma (clinicaltrials.gov) - Feb 15, 2024
P1, N=21, Suspended, Sponsor: City of Hope Medical Center
Trial primary completion date: Dec 2023 --> Dec 2024 Not yet recruiting --> Suspended
- | azeliragon (TTP488) / Cantex Pharma
Trial initiation date: ADORATION: Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (clinicaltrials.gov) - Jan 18, 2024
P1/2, N=46, Recruiting, Sponsor: Baptist Health South Florida
Not yet recruiting --> Suspended Initiation date: Aug 2023 --> Nov 2023
- | azeliragon (TTP488) / Cantex Pharma
Journal: Macrophage RAGE activation is proinflammatory in NASH. (Pubmed Central) - Jan 4, 2024
FFC mice that received a pharmacological inhibitor of RAGE (TTP488), and myeloid-specific RAGE KO mice (RAGE-MKO) had attenuated liver injury associated with a reduced accumulation of RAGE+ recruited macrophages...Correspondingly, the secretome of ligand-stimulated bone marrow derived macrophages from RAGE-MKO mice had an attenuated capacity to activate CD8+ T cells. Our data implicate RAGE as what we propose to be a novel and potentially targetable mediator of the proinflammatory signaling of recruited macrophages in NASH.
- || azeliragon (TTP488) / Cantex Pharma
Enrollment open: Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov) - Oct 27, 2023
P2, N=30, Recruiting, Sponsor: Cantex Pharmaceuticals
Our data implicate RAGE as what we propose to be a novel and potentially targetable mediator of the proinflammatory signaling of recruited macrophages in NASH. Not yet recruiting --> Recruiting
- || azeliragon (TTP488) / Cantex Pharma
Enrollment open, Trial initiation date: CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Sep 15, 2023
P1/2, N=18, Recruiting, Sponsor: Cantex Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Sep 2023
- | azeliragon (TTP488) / Cantex Pharma
Enrollment open: ADORATION: Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (clinicaltrials.gov) - Sep 11, 2023
P1/2, N=46, Recruiting, Sponsor: Baptist Health South Florida
Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Sep 2023 Not yet recruiting --> Recruiting
- || azeliragon (TTP488) / Cantex Pharma
New P2 trial: Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov) - Aug 14, 2023
P2, N=30, Not yet recruiting, Sponsor: Cantex Pharmaceuticals
- | azeliragon (TTP488) / Cantex Pharma
Journal: RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer. (Pubmed Central) - Jul 14, 2023
These results show that TTP488 impairs metastasis of TNBC and further clarifies the signaling and cellular mechanisms through which RAGE mediates metastasis. Importantly, as TTP488 displays a favorable safety profile in human studies, our study provides the rationale for evaluating TTP488 in clinical trials to treat or prevent metastatic TNBC.
- | azeliragon (TTP488) / Cantex Pharma
Trial initiation date: Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma (clinicaltrials.gov) - Jul 5, 2023
P1, N=21, Not yet recruiting, Sponsor: City of Hope Medical Center
Importantly, as TTP488 displays a favorable safety profile in human studies, our study provides the rationale for evaluating TTP488 in clinical trials to treat or prevent metastatic TNBC. Initiation date: Jun 2023 --> Oct 2023
- || azeliragon (TTP488) / Cantex Pharma
Enrollment open, Metastases: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 5, 2023
P1/2, N=18, Recruiting, Sponsor: Cantex Pharmaceuticals
Initiation date: Jun 2023 --> Oct 2023 Not yet recruiting --> Recruiting
- || azeliragon (TTP488) / Cantex Pharma
Review, Journal: RAGE Inhibitors in Neurodegenerative Diseases. (Pubmed Central) - May 16, 2023
Some of the RAGE antagonists, such as Azeliragon, are currently in clinical development for treating neurological diseases, including AD, although currently there have been no FDA-approved therapeutics based on the RAGE antagonists. This review outlines the AGE-RAGE interactions as a leading cause of the onset of neurological diseases and the current efforts on developing therapeutics for neurological diseases based on the RAGE antagonists.
- azeliragon (TTP488) / Cantex Pharma
A preclinical study to evaluate the combination of azeliragon, an inhibitor of the receptor for advanced glycation endproducts (RAGE), with radiation therapy as a potential treatment of glioblastoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4556;
The combination of azeliragon with RT enhances survival in preclinical models. Clinical trials evaluating the safety and efficacy of azeliragon in combination with RT for newly diagnosed GBM are currently under development.
- | azeliragon (TTP488) / Cantex Pharma
Journal: Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. (Pubmed Central) - Apr 25, 2023
Interestingly, afuresertib enhanced the antitumor efficacy of azeliragon in a xenograft mouse model. Collectively, our findings revealed previously unreported aspects of the drug azeliragon, and identified a novel combination strategy for the treatment of pancreatic cancer patients.
- | azeliragon (TTP488) / Cantex Pharma
New P2/3 trial: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia (clinicaltrials.gov) - Apr 18, 2023
P2/3, N=144, Recruiting, Sponsor: Salim S. Hayek
- | azeliragon (TTP488) / Cantex Pharma
New P1/2 trial: ADORATION: Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (clinicaltrials.gov) - Mar 29, 2023
P1/2, N=46, Not yet recruiting, Sponsor: Baptist Health South Florida
- azeliragon (TTP488) / Cantex Pharma
RAGE EXPRESSING MACROPHAGE SUBSETS MEDIATE INFLAMMATION IN NASH (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_1520;
FFC-RLMC-KO and RAGE-i mice had significant attenuation of liver injury compared to FFC-WT and vehicle treated controls respectively, assessed by NAS-grading and ALT. Further, RLMC-KO mice had significantly lower RAGE expression by IHC of liver sections and fibrosis compared to FFC fed WT-mice.
- | azeliragon (TTP488) / Cantex Pharma
New P1 trial: Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma (clinicaltrials.gov) - Mar 17, 2023
P1, N=21, Not yet recruiting, Sponsor: City of Hope Medical Center
- || azeliragon (TTP488) / Cantex Pharma
New P1/2 trial, Metastases: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 13, 2023
P1/2, N=18, Not yet recruiting, Sponsor: Cantex Pharmaceuticals
- | azeliragon (TTP488) / Cantex Pharma
Trial initiation date: CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Mar 10, 2023
P1/2, N=18, Not yet recruiting, Sponsor: Cantex Pharmaceuticals
Further, RLMC-KO mice had significantly lower RAGE expression by IHC of liver sections and fibrosis compared to FFC fed WT-mice. Initiation date: Dec 2022 --> Mar 2023
- ||| azeliragon (TTP488) / Cantex Pharma
Another interesting compound to watch. Could #azeliragon treat #gbm & reduce cognitive harm? Small study to start. #btsm #glioblastoma (Twitter) - Jan 22, 2023
- ||| azeliragon (TTP488) / Cantex Pharma
FDA event, Orphan drug: $VTVT CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA https://t.co/nP09xJ8mDa (Twitter) - Jan 9, 2023
- | Enrollment open, Trial completion date, Trial primary completion date: RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) - Jan 9, 2023
P1/2, N=48, Recruiting, Sponsor: Georgetown University
Initiation date: Dec 2022 --> Mar 2023 Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- | azeliragon (TTP488) / Cantex Pharma
Journal, Metastases: Blockade of receptor for advanced glycation end-products with azeliragon ameliorates streptozotocin-induced diabetic neuropathy. (Pubmed Central) - Dec 30, 2022
These drug treatments had no effect on blood glucose levels. Our findings suggest that RAGE might be an effective target for diabetic neuropathy treatment.
- || azeliragon (TTP488) / Cantex Pharma
New P1/2 trial: CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Dec 2, 2022
P1/2, N=18, Not yet recruiting, Sponsor: Cantex Pharmaceuticals
- | azeliragon (TTP488) / Cantex Pharma
Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker: RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice. (Pubmed Central) - Oct 19, 2022
The RAGE antagonist prevented xenograft rejection by human immune cells in a murine model. A RAGE antagonist may be a useful inhibitor of adaptive human immune responses.
- azeliragon (TTP488) / Cantex Pharma
Azeliragon (TTP488), an orally- available small molecule RAGE inhibitor, reduces metastasis in preclinical mouse models of breast cancer (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1166;
These results show that TTP488 impairs metastasis of multiple highly aggressive TNBC models for the first time. Importantly, as TTP488 displays a high safety profile in human trials, this study provides the rationale for evaluating TTP488 in clinical trials to treat or prevent metastatic breast cancer.
- | Trial initiation date: RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) - Sep 29, 2022
P1/2, N=48, Not yet recruiting, Sponsor: Georgetown University
Importantly, as TTP488 displays a high safety profile in human trials, this study provides the rationale for evaluating TTP488 in clinical trials to treat or prevent metastatic breast cancer. Initiation date: Aug 2022 --> Nov 2022
- | Trial initiation date: RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) - Jun 14, 2022
P1/2, N=48, Not yet recruiting, Sponsor: Georgetown University
Initiation date: Aug 2022 --> Nov 2022 Initiation date: May 2022 --> Aug 2022